Agios Pharmaceuticals (AGIO) Net Cash Flow (2012 - 2026)

Agios Pharmaceuticals (AGIO) has 15 years of Net Cash Flow data on file, last reported at -$14.0 million in Q2 2026.

• Quarterly Net Cash Flow fell 831.67% year-over-year to -$14.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $18.8 million (up 614.83% YoY) and the FY2025 annual result came in at $12.9 million, up 207.74% from the prior year.
• Net Cash Flow slipped to -$14.0 million in Q2 2026, from $24.5 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $169.2 million in Q3 2024 to a low of -$177.5 million in Q4 2024.
• A 5-year average of -$5.7 million and a median of $2.3 million in 2025 frame the typical range for Net Cash Flow.
• The widest YoY moves for Net Cash Flow: up 928.66% in 2024, down 843.48% in 2024.
• Tracing AGIO's Net Cash Flow over 5 years: stood at $16.8 million in 2022, then jumped by 42.01% to $23.9 million in 2023, then sank by 843.48% to -$177.5 million in 2024, then soared by 97.98% to -$3.6 million in 2025, then sank by 289.75% to -$14.0 million in 2026.
• The last three Net Cash Flow figures came in at -$14.0 million (Q2 2026), $24.5 million (Q1 2026), and -$3.6 million (Q4 2025), per Business Quant data.